Zeo ScientifiX (ZEOX) Return on Capital Employed (2013 - 2026)
Zeo ScientifiX (ZEOX) posted quarterly Return on Capital Employed of 3514.04% for Q2 2026, down 378132.0% year-over-year from N/an in Q2 2025, and down 686.96% quarter-over-quarter from 598.69% in Q1 2026.
Zeo ScientifiX (ZEOX) Return on Capital Employed (2013 - 2026) Analysis & Trends
Zeo ScientifiX's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 3514.04% for Q2 2026.
- In Q2 2026, Return on Capital Employed fell 378132.0% year-over-year to 3514.04%; the TTM figure through Apr 2026 stood at 3514.04% (down 378132.0% YoY), while the FY2025 annual figure was 418.17%, down 7639.0% from the prior year.
- Return on Capital Employed for Q2 2026 stood at 3514.04%, down from 598.69% in the prior quarter.
- The five-year high for Return on Capital Employed was 2070.74% in Q3 2023, with the low at 3514.04% in Q2 2026.
- The 5-year median for Return on Capital Employed is 287.99% (2025), against an average of 123.7%.
- The sharpest annual moves came in 2023 and 2026: Return on Capital Employed surged 328406 bps in 2023, then tumbled 378132 bps in 2026.
- Zeo ScientifiX's Return on Capital Employed stood at 2797.63% in 2022, then soared by 117 bps to 486.43% in 2023, then retreated by 19 bps to 392.26% in 2024, then advanced by 7 bps to 419.63% in 2025, then plunged by 937 bps to 3514.04% in 2026.
- Business Quant data shows ZEOX's Return on Capital Employed at 3514.04% in Q2 2026, 598.69% in Q1 2026, and 419.63% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Zeo ScientifiX | 10.51 Mn | 8.67 Mn | 2.06 Mn | -3,514.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -3,514.04% |
| Jan 31, 2026 | 598.69% |
| Oct 31, 2025 | 419.63% |
| Jul 31, 2025 | 263.48% |
| Apr 30, 2025 | 267.28% |
| Jan 31, 2025 | 308.70% |
| Oct 31, 2024 | 392.26% |
| Jul 31, 2024 | 329.12% |
| Apr 30, 2024 | 375.54% |
| Jan 31, 2024 | 437.16% |
| Oct 31, 2023 | 486.43% |
| Jul 31, 2023 | 2,070.74% |
| Apr 30, 2023 | -1,846.86% |
| Jan 31, 2023 | -511.47% |
| Oct 31, 2022 | -2,797.63% |
| Jul 31, 2022 | 148.09% |
| Apr 30, 2022 | 134.88% |
| Jan 31, 2022 | 211.38% |
| Oct 31, 2021 | 553.66% |
| Jul 31, 2021 | 700.86% |